Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.

Yinghong ZhaiFangyuan HuWentao ShiXiaofei YeJingfang XuXiaojing GuoDhanisha Jayesh TrivediJia HeFeng Xu

Published in: Expert opinion on drug safety (2023)

Receiving ibrutinib, acalabrutinib or zanubrutinib might increase the chance of cardiac complications, with ibrutinib posing the highest risk. The type of cardiotoxicity involved in ibrutinib was highly variable.

Keyphrases

chronic lymphocytic leukemia
left ventricular
human health
adverse drug
emergency department
heart failure
climate change
breast cancer risk